New study finds apoB blood test beats standard LDL screening
New CapabilitiesA Northwestern model of 250,000 adults shows counting cholesterol particles, not measuring their contents, prevents more heart attacks at a cost payers can absorb
July 6th, 2026: Findings reach a wide audienceNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated Jul 7Most Americans who get their cholesterol checked receive an LDL test. A Northwestern Medicine study says a different, rarely ordered test would catch more of the people about to have a heart attack.
The test is apolipoprotein B, or apoB. It counts the actual number of harmful cholesterol particles in your blood, rather than measuring the cholesterol packed inside them. In a model of 250,000 U.S. adults, guiding treatment by apoB prevented more heart attacks and strokes than the standard LDL approach, and did so at a price researchers call good value for health payers.
Why it matters
Heart disease kills more Americans than anything else. A cheap test many patients have never heard of could flag more of the people most likely to die from it.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
The Chicago medical school whose researchers built the model comparing cholesterol-testing strategies.
The heart-health nonprofit that funded the study and helped write the 2026 guidelines emphasizing apoB.
Timeline
August 2019 July 2026
-
Findings reach a wide audience
Latest PublicityNews coverage brings the study to general readers, framing apoB as a test millions of patients are not getting.
-
ACC publishes practitioner guide to the new dyslipidemia guidelines
GuidelineThe American College of Cardiology publishes a clinician-facing article — "Lower Sooner" — laying out when and how to add apoB testing under the updated 2026 standards.
-
JAMA publishes the Northwestern study
ResearchNorthwestern researchers report that apoB-guided treatment prevents more heart attacks and strokes than LDL targets, at a cost payers can absorb.
-
ACC and AHA release 2026 dyslipidemia guidelines
GuidelineAn 11-society joint guideline raises apoB's clinical standing — recommending it for patients where LDL may underestimate risk — but keeps it as a confirmatory measure, not a primary screen. It also makes universal once-in-a-lifetime Lp(a) screening a Class I recommendation for all adults.
-
European guidelines flag apoB
GuidelineEuropean cardiology and atherosclerosis societies name apoB a useful marker for cardiovascular risk, especially for certain patients.
Historical Context
2 moments from history that rhyme with this story — and how they unfolded.
Statins move to primary prevention (2008)
The JUPITER trial showed rosuvastatin cut heart attacks and strokes in people with normal LDL but high C-reactive protein. It challenged the idea that LDL alone decides who needs treatment. The result reached about 18,000 participants.
Guidelines and prescribing widened to include patients LDL testing had passed over.
Risk-based treatment, not a single cholesterol number, became the model for prevention.
Like JUPITER, the apoB study argues the standard number misses people who are actually at risk.
HbA1c replaces fasting glucose for diabetes (2009-2010)
An international expert panel recommended the HbA1c blood test to diagnose diabetes. It measured long-term blood sugar and did not require fasting. Major bodies adopted it soon after.
Clinicians gained a more convenient, more stable test for identifying patients.
HbA1c became a routine standard, showing how a better metric can displace an entrenched one.
Shows the path apoB advocates hope to follow: a better measure becoming the default, if convenience and cost line up.
